Skip to main content

Table 1 Major clinical trials of elotuzumab that have published data

From: Elotuzumab for the treatment of multiple myeloma

Study NCT number (trial name) Phase N Regimen ORR PFS rate Median PFS (months)
Zonder 2012 [23] NCT00425347
(HuLuc63-1701)
1 35a Elotuzumab (0.5–20 mg/kg) 0
Lonial 2012 [26, 27] NCT00742560
(HuLuc63-1703)
1b 29b Elotuzumab (5–20 mg/kg) + Rd 82 % 32.9
Richardson 2015 [27] NCT00742560
(HuLuc63-1703)
2 36 Elotuzumab (10 mg/kg) + Rd 92 %   32.5c
37 Elotuzumab (20 mg/kg) + Rd 76 %   25.0c
Lonial 2015 [32] NCT01239797
(ELOQUENT-2)
3 321 Elotuzumab (10 mg/kg) + Rd 79 % 1-year 68 %, 2-year 41 % 19.4
325 Rd 66 % 1-year 57 %, 2-year 27 % 14.9
Mateos 2014 [34] NCT01632150 2 40 Elotuzumab (10 mg/kg) + TDd 40 %
Jakubowiak 2012 [35] NCT00726869
(HuLuc63-1702)
1 28 Elotuzumab (2.5–20 mg/kg) + V 48 %   9.46e
Palumbo 2015 [38]
Jakubowiak 2016 [39]
NCT01478048 1/2 77f Elotuzumab (10 mg/kg) + VD 66 % 1-year 39 %, 2-year 18 % 9.7
75 VD 63 % 1-year 33 %, 2-year 11 % 6.9
  1. N number; ORR objective response rate; PFS progression-free survival; Rd lenolidomide and dexamethasone; TD thalidomide and dexamethasone; V bortezomib; VD bortezomib and dexamethasone
  2. aThirty-four patients treated
  3. bTwenty-eight patients treated
  4. cMedian time to progression or death
  5. dCyclophosphamide was added if progressing between cycle 2 and 5 or not responding by cycle 5
  6. eMedian time to progression
  7. fSeventy-five patients treated